Figure 2.

The cefazolin-MIC-related trend (all γ = 1.00, p = 0.01) in primary and secondary outcomes of adults with community-onset monomicrobial Escherichia coli, Klebsiella species, or Proteus mirabilis bacteremia definitively treated by cefazolin. Early treatment failure, i.e., primary outcome, was the composite of antimicrobial escalation to broad-spectrum agents, the development of breakthrough bacteremia, the need for intensive care during definitive cefazolin therapy, and crude mortality within 15 days after bacteremia onset.